Phone: 1.510.856.5600|info@anthera.com

Press Releases

 
Press Releases
  Date Title and Summary View
Mar 29, 2017
Sollpura demonstrated comparable maintenance in key measurements of height, weight, and BMISollpura was well tolerated throughout the 20-Week Extension Period HAYWARD, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the findings from the Extension Period of the Phase 3 SOLUTION, non-inferior...
Mar 14, 2017
HAYWARD, Calif., March 14, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) (the "Company") today announced the pricing of an underwritten public offering of 30,000,000 shares of its common stock at a price of $0.50 per share and two tranches of warrants to purchase an aggregate of 60,000,000 shares of its common stock. The gr...
Mar 13, 2017
HAYWARD, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) (the "Company") today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.  In addition, the Company intends to grant the underwriters a 30-day op...
Feb 27, 2017
SOLUTION study with Sollpura™ missed non-inferiority endpoint by 1%, prompting new phase 3 studyData Monitoring Committee issued recommendation to continue SIMPLICITY study with Sollpura™Blisibimod for the treatment of IgA Nephropathy demonstrated positive trends at week 48Blisibimod for the treatment of systemic lupus terminatedCraig T...
Dec 27, 2016
Sollpura narrowly missed the primary endpoint for change in the Coefficient of Fat Absorption (CFA) non-inferiority marginSollpura demonstrated non-inferiority in the per protocol CFA analysisSollpura demonstrated non-inferiority in Coefficient of Nitrogen Absorption (CNA) analysesAnthera will initiate a new study to demonstrate the efficacy of Sol...
Dec 13, 2016
HAYWARD, Calif., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that the Data Monitoring Committee (DMC) completed its pre-planned safety review of the SIMPLICITY clinical study of Sollpura supplied as a powder for oral solution in an initial cohort of cystic fibrosis patients  seven years of age and...
Dec 6, 2016
J. Craig Thompson promoted to Chief Executive Officer and appointed to the Board of DirectorsPaul F. Truex appointed as Executive Chairman of the BoardDr. Christopher Henney stepped down as Chairman of the Board but will remain as Director HAYWARD, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Today the Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) Boa...
Dec 6, 2016
Lower proteinuria in blisibimod versus placebo treated patientsChanges in circulating B-cells and serum immunoglobulins consistent with BAFF inhibition HAYWARD, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced positive trends from the Week 48 analysis of the Phase 2 BRIGHT-SC proof-of-concept...
Nov 22, 2016
Nov 10, 2016
Assessing next steps for blisibimod for the treatment of Systemic Lupus ErythematosusContinuing to explore blisibimod as treatment for IgA nephropathy - Phase 2 data in DecemberSollpuraTM SOLUTION phase 3 study in exocrine pancreatic insufficiency on track for topline data in December HAYWARD, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Anthera ...
Page:
1
... NextLast
= add release to Briefcase
Print Friendly